Keryx Biopharmaceuticals Inc (KERX): Brian Adams , VP and General Counsel of Keryx Biopharmaceuticals Inc sold 1,083 shares on Jul 15, 2016. The Insider selling transaction was reported by the company on Jul 18, 2016 to the Securities and Exchange Commission. The shares were sold at $7.01 per share for a total value of $7,591.83 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 6, 2016, Brian Adams (VP and General Counsel) sold 660 shares at $6.66 per share price.On Jul 6, 2016, Greg Madison (President and CEO) sold 936 shares at $6.66 per share price.Also, On Apr 27, 2016, John F. Neylan (Chief Medical Officer) sold 4,766 shares at $5.21 per share price.On Nov 5, 2015, Scott A Holmes (CFO) purchased 5,000 shares at $5.35 per share price.
Keryx Biopharmaceuticals: On Friday, Jul 15, 2016 heightened volatility was witnessed in Keryx Biopharmaceuticals which led to swings in the share price. The shares opened for trading at $7.07 and hit $7.1694 on the upside , eventually ending the session at $7.09, with a gain of 1.14% or 0.08 points. The heightened volatility saw the trading volume jump to 9,98,479 shares. The 52-week high of the share price is $10.51 and the company has a market cap of $750 M . The 52-week low of the share price is at $2.8.
Company has been under the radar of several Street Analysts.Keryx Biopharmaceuticals is Reiterated by Maxim Group to Buy and the brokerage firm has raised the Price Target to $ 9 from a previous price target of $7 .The Rating was issued on Jul 8, 2016.
Keryx Biopharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate) an oral absorbable iron-based compound received marketing approval from the United States Food and Drug Administration (FDA) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels Auryxia’s pharmacodynamic properties resulted in increased ferritin iron and transferrin saturation (TSAT).